Sympathetic nervous system alterations with HER2+ antagonism: an early marker of cardiac dysfunction with breast cancer treatment?

BACKGROUND: HER2 antagonists (anti-HER2; e.g., trastuzumab and lapatinib) are effective in treating an aggressive form of breast cancer (BC), but can cause cardiotoxicity due to the disruption in neuregulin (NRG)/HER2+ ligand receptor signalling. The recent data show that NRG-HER2 receptors located...

Descripción completa

Detalles Bibliográficos
Autores principales: Lenneman, Carrie G, Abdallah, Wissam M, Smith, Holly M, Abramson, Vandana, Mayer, Ingrid A, Silverstein, Cheri, Means-Powell, Julie, Paranjape, Sachin Y, Lenihan, Daniel, Sawyer, Douglas B, Raj, Satish R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2014
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4118731/
https://www.ncbi.nlm.nih.gov/pubmed/25114718
http://dx.doi.org/10.3332/ecancer.2014.446

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4118731/
https://www.ncbi.nlm.nih.gov/pubmed/25114718
http://dx.doi.org/10.3332/ecancer.2014.446

Ejemplares similares